Eli Lilly and Company (LLY)
Are Medical Stocks Lagging Eli Lilly (LLY) This Year?
Here is how Eli Lilly (LLY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
Eli Lilly's weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Eli Lilly's Weight Loss Drugs No Longer In Shortage. It's Bad News for These Stocks.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list.
Supply Issues Resolved for Eli Lilly's (LLY) Zepbound and Mounjaro
The U.S. Food and Drug Administration (FDA) has announced that the supply shortages of Eli Lilly's (LLY, Financial) popular weight-loss and diabetes medications, Zepbound and Mounjaro, have been resolved. This resolution may impact the market presence of generic versions that had become popular due to previous shortages.
Eli Lilly (LLY) Solves U.S. Shortage of Mounjaro and Zepbound, Plans Major Expansion
The U.S. Food and Drug Administration (FDA) recently announced that the shortage of Eli Lilly's weight loss medications, Mounjaro and Zepbound, has been resolved. While these drugs, which contain tirzepatide, are now more readily available, patients and prescribers might still face occasional local shortages as they move through the supply chain.
US FDA says Lilly's weight-loss drug no longer in shortage
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday.
Eli Lilly CEO: We have 11 pipeline projects in obesity
CNBC's Angelica Peebles joins 'Squawk on the Street' to report on Eli Lilly's new investment in a new $4.5 billion research and development center.
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Eli Lilly and Co LLY is making a major move with a $4.5 billion investment to create the Lilly Medicine Foundry, a new research and manufacturing facility.
Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
Lilly announces new $4.5 bln manufacturing site in Indiana
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and drug development in Indiana.
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
